Article
Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2
2021-12-21
Abstract excerpt
<h4>Summary</h4> Antisense oligonucleotide therapy targeting ATXN2 —a gene in which mutations cause neurodegenerative diseases spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis—has entered clinical trials in humans. Additional methods to lower ataxin-2 levels would be beneficial not only in uncovering potentially cheaper or less invasive therapies, but also in gaining greater mechanistic insight in...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 71715a8d-a6df-5bd7-87a8-53419ea8bb3c
- DOI
- 10.1101/2021.12.20.473567
